Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, NIH, Bethesda, MD 20892-4330, USA.
Cancer Discov. 2013 Jul;3(7):722-5. doi: 10.1158/2159-8290.CD-13-0239.
Two studies published in this issue of Cancer Discovery describe the emerging mutational landscape of head and neck squamous cell carcinomas (HNSCC) and their genomic and epigenetic alterations, thus identifying novel actionable cancer drivers and predictive biomarkers for targeted therapies. Most genomic alterations in HNSCC converge in a handful of molecular pathways, resulting in cell-cycle deregulation, genomic instability, cell differentiation defects, and persistent mitogenic signaling, the latter involving aberrant phosphoinositide 3-kinase (PI3K)/mTOR pathway activation, thereby rendering HNSCC responsive to PI3K/mTOR inhibitors. Cancer Discov; 3(7); 722-5. ©2013 AACR.
本期《癌症发现》杂志发表的两项研究描述了头颈鳞状细胞癌(HNSCC)不断出现的突变特征及其基因组和表观遗传改变,从而确定了新型可操作的癌症驱动基因和针对靶向治疗的预测性生物标志物。HNSCC 中的大多数基因组改变都集中在少数几个分子途径中,导致细胞周期失调、基因组不稳定、细胞分化缺陷和持续的有丝分裂信号,后者涉及异常的磷酸肌醇 3-激酶(PI3K)/哺乳动物雷帕霉素靶蛋白(mTOR)途径激活,从而使 HNSCC 对 PI3K/mTOR 抑制剂敏感。Cancer Discov; 3(7); 722-5. ©2013 AACR.